Biogen to Strengthen Immunology Pipeline With $1B RayThera Buyout

BIIB is set to acquire RayThera for up to $1 billion, adding anti-inflammatory candidates that could expand its immunology pipeline and future growth.

Zacks Investment Research • Jun 18, 2026

GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections

GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.

Zacks Investment Research • Jun 18, 2026

US FDA approves GSK's oral antibiotic for drug-resistant UTIs

The U.S. ​FDA has ‌approved GSK's oral ​antibiotic ​to treat complicated ⁠urinary ​tract infections, ​the regulator said on ​Wednesday, ​giving patients a ‌new ⁠treatment option against drug-resistant ​infections.

Reuters • Jun 17, 2026

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii in adult patients who have limited or no alternative oral treatment options. This is the first and only oral carbapenem antibiotic approved for these patients. This app.

Business Wire • Jun 17, 2026

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC.  Many biotech companies are now pursuing a dual-track process: preparing for an IPO while simultaneously engaging with potential acquirers.

CNBC • Jun 16, 2026

FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

Zacks Investment Research • Jun 16, 2026

GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder

GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.

Zacks Investment Research • Jun 12, 2026

Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal

GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks ​to fend off competition from bigger rivals AstraZeneca and Roche.

Reuters • Jun 11, 2026

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.

MarketBeat • Jun 11, 2026

Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines

Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.

Zacks Investment Research • Jun 11, 2026